AI assistant
Nuvalent, Inc. — Director's Dealing 2024
Jun 14, 2024
30903_dirs_2024-06-14_fad62b0b-98b2-4e7a-9104-d2d3c522308a.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: Nuvalent, Inc. (NUVL)
CIK: 0001861560
Period of Report: 2024-06-12
Reporting Person: Hack Andrew A. F. (N/A)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2024-06-12 | Class A Common Stock | A | 2499 | — | Acquired | 2499 | Direct |
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2024-06-12 | Stock Option (right to buy) | $80.03 | A | 3789 | Acquired | 2034-06-12 | Class A Common Stock (3789) | Direct |
Holdings (Non-Derivative)
| Security | Shares | Ownership |
|---|---|---|
| Class A Common Stock | 2697267 | Indirect |
Footnotes
F1: The shares reported in this transaction represent Restricted Stock Units ("RSUs"). Each RSU represents the contingent right to receive one share of the Issuer's Class A Common Stock. 100% of the RSUs subject to this grant will vest on the earlier of June 12, 2025 or the date of the Issuer's next annual meeting of stockholders, subject to continued service to the Issuer through such vesting date.
F2: The shares underlying this option will vest in full on the earlier of June 12, 2025 or the date of the Issuer's next annual meeting of stockholders, subject to continued service to the Issuer through such vesting date.
F3: Represents shares of Class A Common Stock held directly by Bain Capital Life Sciences Fund II, L.P. ("BCLS Fund II"), BCIP Life Sciences Associates, LP ("BCIPLS") and BCLS II Investco, LP ("BCLS II Investco" and, together with BCLS Fund II and BCIPLS, the "Bain Capital Life Sciences Entities").
F4: Bain Capital Life Sciences Investors, LLC ("BCLSI") is the ultimate general partner of each of BCLS Fund II and BCLS II Investco and governs the investment strategy and decision-making process with respect to investments held by BCIPLS. Dr. Hack is a Partner of BCLSI. By virtue of the relationships described in this footnote, Dr. Hack may be deemed to share voting and dispositive power with respect to the securities held by the Bain Capital Life Sciences Entities. Dr. Hack disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein.